CYP3A43 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Telithromycin (SCHEMBL5100)	1.00	6/20
Telithromycin (SCHEMBL5101)	1.00	6/20
Telithromycin (SCHEMBL784845)	1.00	6/20
SCHEMBL784787	0.76	3/20
SCHEMBL1165314	0.47	3/20
SCHEMBL971260	0.42	3/20
SCHEMBL971261	0.40	3/20
SCHEMBL84978	0.84	2/20
SCHEMBL84543	0.79	2/20
SCHEMBL196765	0.73	2/20
SCHEMBL784963	0.72	2/20
SCHEMBL84929	0.70	2/20
SCHEMBL84985	0.70	2/20
SCHEMBL85532	0.69	2/20
SCHEMBL84517	0.69	2/20
SCHEMBL84914	0.68	2/20
SCHEMBL84919	0.68	2/20
SCHEMBL85531	0.68	2/20
SCHEMBL84994	0.68	2/20
SCHEMBL1180429	0.67	2/20

Clinical trials — most relevant to CYP3A43 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies	PHASE4	RECRUITING
Physiological Study of the Human CYP3A Activity (PiSA)	PHASE4	COMPLETED
Proton Pump Inhibitor Preventing Upper Gastrointestinal Injury In Patients On Dual Antiplatelet Therapy After CABG	PHASE4	UNKNOWN
OPTImization of the Dose of tacroliMUS by Bayesian Prediction	PHASE4	COMPLETED
Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm	PHASE4	NOT_YET_RECRUITING
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma	PHASE2	NOT_YET_RECRUITING
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
Asciminib in HER2+ Breast Cancer Brain Metastases	PHASE1/PHASE2	NOT_YET_RECRUITING
3 Month PHI PAD PoM Study	PHASE2	COMPLETED
Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia	PHASE2	COMPLETED
Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers	PHASE1	COMPLETED
Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults	PHASE1	COMPLETED
AZD1981 Midazolam CYP4503A Induction Study	PHASE1	COMPLETED
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension	PHASE1	COMPLETED
Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites	PHASE1	COMPLETED
To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants	PHASE1	COMPLETED
Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects	PHASE1	COMPLETED
BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma	PHASE1	COMPLETED
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors	PHASE1	RECRUITING
A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies	PHASE1	UNKNOWN
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients	nan	COMPLETED
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia	nan	NOT_YET_RECRUITING
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis	nan	COMPLETED
Influence of CYP2C19 Genotype on Safety and Efficacy of Voriconazole in Pediatric Patients With Hematologic Malignancy	nan	UNKNOWN
Metabolism of Chlordiazepoxide in the Treatment of Alcohol Withdrawal Symptoms	nan	COMPLETED
Blood Levels of Ketamine in Patients Using Topical Application of 10% Ketamine Gel for Neuropathic Pain	nan	UNKNOWN
CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer Patients	nan	UNKNOWN
Effects of Genotype on CYP2C9 Drug Interactions	nan	COMPLETED
Voriconazole Blood Level and Liver Metabolizing Enzyme in Taiwanese Patients	nan	COMPLETED
CYP2C19 Variants and Limonene Metabolism	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CYP3A43 binder may also engage these)

Protein	Name	Similarity
Q64581	—	1.000	Q64581 →
Q64481	—	1.000	Q64481 →
P05183	—	1.000	P05183 →
Q64459	—	1.000	Q64459 →
Q64409	—	1.000	Q64409 →
Q9PVE8	—	0.999	Q9PVE8 →
Q64406	—	0.998	Q64406 →
O09158	—	0.997	O09158 →
P79102	—	0.997	P79102 →
P33268	—	0.997	P33268 →
Q8AXY5	—	0.996	Q8AXY5 →
Q64148	—	0.996	Q64148 →
P79401	—	0.996	P79401 →
O70537	—	0.995	O70537 →
Q64464	—	0.995	Q64464 →
CYP3A7	Cytochrome P450 3A7	0.995	landscape →
O18993	—	0.994	O18993 →
P24463	—	0.993	P24463 →
Q64417	—	0.993	Q64417 →
CYP3A4	Cytochrome P450 3A4	0.993	landscape →
Q9JMA7	—	0.992	Q9JMA7 →
Q27664	—	0.992	Q27664 →
Q9V770	—	0.991	Q9V770 →
Q964T1	—	0.991	Q964T1 →
Q95036	—	0.991	Q95036 →
CYP3A5	Cytochrome P450 3A5	0.990	landscape →
Q98T91	—	0.990	Q98T91 →
Q964R1	—	0.989	Q964R1 →
Q964R0	—	0.989	Q964R0 →
P51538	—	0.989	P51538 →